Biohaven CEO says drug approval is ‘monumental’ for migraine patients

62
18
Favorite

Biohaven CEO says drug approval is ‘monumental’ for migraine patients

cnbc2021-06-09

Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（18）

Winkingbear
·2021-06-09
Interesting news that’s not corona
Reply
1
Report
Fold Replies
- Jomum:
  Yea
  2021-06-09
  Reply
  Report
BarleyIce
·2021-06-09
Like and comment thanksss
Reply
1
Report
Fold Replies
- HappyCloud:
  Pls comment too.
  2021-06-09
  Reply
  Report
Deonc
·2021-06-09
Good news
Reply
Like
Report
Yinasim
·2021-06-09
This will be good news for chronic migraine sufferers.
Reply
Like
Report
Fold Replies
- 慢的老人:
  Yes, but I am pretty sure the company will start jacking up the price for this drug now. $$$
  2021-06-09
  Reply
  Report
- Yinasim:
  I guess they have to, to recoup their R&D costs.
  2021-06-09
  Reply
  Report
Waqwaq
·2021-06-09
Just waiting for my neurologist to tell me about this. But the Aimovig jab works for me
Reply
Like
Report
desjen
·2021-06-09
Hi pls like and comment thx!
Reply
3
Report
Fold Replies
- desjen:
  Thanks
  2021-06-14
  Reply
  Report
- desjen:
  Thanks and pls reply and like
  2021-06-09
  Reply
  Report
- Ak91:
  Comment back pls
  2021-06-09
  Reply
  Report
View more 1 comments
Roticanai
·2021-06-09
Like
Reply
7
Report
Kikiooi
·2021-06-09
Sometimes tihinong is the drug approval become too fast, lacking of longer analysis or long let term clinical data?
Reply
1
Report
Brandon2207
·2021-06-09
Like and comment please
Reply
2
Report
Fold Replies
- JerlinTan:
  done, pls response back
  2021-06-09
  Reply
  Report
- Couragesther:
  Sure hElp comMent back
  2021-06-09
  Reply
  Report
A79
·2021-06-09
Not sure abt thatBut like and comment here for good luck!
Reply
3
Report
Fold Replies
- Shop:
  [Smile]
  2021-06-09
  Reply
  Report
- AhGong:
  done
  2021-06-09
  Reply
  Report
- Brandon2207Replying toShop:
  Please like back
  2021-06-09
  Reply
  Report
JaydenSee
·2021-06-09
Pls like and comments
Reply
4
Report
Fold Replies
- Acella:
  ?
  2021-06-09
  Reply
  Report
- JerlinTan:
  done, pls response back
  2021-06-09
  Reply
  Report
nayoowin
·2021-06-09
Good
Reply
1
Report
Dickson8614
·2021-06-09
Please like and comment
Reply
5
Report
Fold Replies
- Acella:
  ?
  2021-06-09
  Reply
  Report
- cutemiao:
  Interesting. Like and comment back. Thanks
  2021-06-09
  Reply
  Report
- JaydenSee:
  ok
  2021-06-09
  Reply
  Report
View more 2 comments
EsmeT
·2021-06-09
Like and comment too pls!
Reply
5
Report
Fold Replies
- HappyTum:
  Done
  2021-06-09
  Reply
  Report
- EsmeT:
  Thanks!
  2021-06-09
  Reply
  Report
Jinroro
·2021-06-09
Oh
Reply
1
Report
Ladious
·2021-06-09
Comment an like
Reply
5
Report
Fold Replies
- EsmeT:
  ??
  2021-06-09
  Reply
  Report
- Ladious:
  help
  2021-06-09
  Reply
  Report
Shop
·2021-06-09
comment n like
Reply
3
Report
Fold Replies
- YH999:
  reply pls
  2021-06-09
  Reply
  Report
- EsmeT:
  ??
  2021-06-09
  Reply
  Report
hmmwvms
·2021-06-09
Headache
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1111279529?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-09 08:56","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1111279529","market":"us","top_or_hot":-1,"title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","media":"cnbc","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Source Link</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BHVN","symbol_name":"Biohaven Pharmaceutical Holding Co Ltd.","start_time":0,"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","article_id":"1111279529","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","pubTimestamp":1623200185,"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"translate_title":"Biohaven首席执行官说，药物批准对偏头痛患者来说是“巨大的”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":180658538,"gmtCreate":1623202883324,"gmtModify":1704198246444,"author":{"id":"3566159832938847","authorId":"3566159832938847","name":"Winkingbear","avatar":"https://static.tigerbbs.com/fa59ca544b59fdba57ec5b04668be509","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Interesting news that’s not corona&nbsp;","listText":"Interesting news that’s not corona&nbsp;","text":"Interesting news that’s not corona","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/180658538","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4644840,"gmtCreate":1623212389840,"gmtModify":1663228259343,"authorId":3581711420498497,"author":{"id":3581711420498497,"authorId":3581711420498497,"name":"Jomum","avatar":"https://static.tigerbbs.com/4f76fac17668e3f2183dc6576449da0a","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180658538,"type":1,"supId":0,"prevId":0,"content":"Yea","text":"Yea","html":"Yea"}],"langContent":"EN"},{"id":180685240,"gmtCreate":1623201906980,"gmtModify":1704198206904,"author":{"id":"3562802954762393","authorId":"3562802954762393","name":"BarleyIce","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and comment thanksss","listText":"Like and comment thanksss","text":"Like and comment thanksss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/180685240","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4642343,"gmtCreate":1623201978242,"gmtModify":1663228245458,"authorId":3568154809054444,"author":{"id":3568154809054444,"authorId":3568154809054444,"name":"HappyCloud","avatar":"https://static.tigerbbs.com/39dc69f5461d4fc413d626e66aa91a90","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.06","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180685240,"type":1,"supId":0,"prevId":0,"content":"Pls comment too. ","text":"Pls comment too. ","html":"Pls comment too. "}],"langContent":"EN"},{"id":180685159,"gmtCreate":1623201887471,"gmtModify":1704198206742,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180685159","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180682522,"gmtCreate":1623201862466,"gmtModify":1704198206579,"author":{"id":"3585236324784959","authorId":"3585236324784959","name":"Yinasim","avatar":"https://community-static.tradeup.com/news/fe636395860151da4253481e4a32fd0d","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"This will be good news for chronic migraine sufferers.&nbsp;","listText":"This will be good news for chronic migraine sufferers.&nbsp;","text":"This will be good news for chronic migraine sufferers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/180682522","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4642715,"gmtCreate":1623203002444,"gmtModify":1663228248634,"authorId":3582028884093480,"author":{"id":3582028884093480,"authorId":3582028884093480,"name":"慢的老人","avatar":"https://static.tigerbbs.com/d8809bb976396889eb133162af0901b8","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.08","exceedPercentage":"80.04%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180682522,"type":1,"supId":0,"prevId":0,"content":"Yes, but I am pretty sure the company will start jacking up the price for this drug now. $$$","text":"Yes, but I am pretty sure the company will start jacking up the price for this drug now. $$$","html":"Yes, but I am pretty sure the company will start jacking up the price for this drug now. $$$"},{"id":4642924,"gmtCreate":1623203820553,"gmtModify":1663228248427,"authorId":3585236324784959,"author":{"id":3585236324784959,"authorId":3585236324784959,"name":"Yinasim","avatar":"https://community-static.tradeup.com/news/fe636395860151da4253481e4a32fd0d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180682522,"type":1,"supId":4642715,"prevId":0,"content":"I guess they have to,&nbsp; to recoup their R&amp;D costs.","text":"I guess they have to,&nbsp; to recoup their R&amp;D costs.","html":"I guess they have to,&nbsp; to recoup their R&amp;D costs."}],"langContent":"EN"},{"id":180683969,"gmtCreate":1623201687151,"gmtModify":1704198199495,"author":{"id":"3582090760348992","authorId":"3582090760348992","name":"Waqwaq","avatar":"https://static.tigerbbs.com/26d60cb35d5f8de1725460e2291836fb","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Just waiting for my neurologist to tell me about this. But the Aimovig jab works for me","listText":"Just waiting for my neurologist to tell me about this. But the Aimovig jab works for me","text":"Just waiting for my neurologist to tell me about this. But the Aimovig jab works for me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180683969","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180612601,"gmtCreate":1623201490003,"gmtModify":1704198191491,"author":{"id":"3569967413953406","authorId":"3569967413953406","name":"desjen","avatar":"https://static.tigerbbs.com/4314e7f661d526ed72ecededb19043c2","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"Hi pls like and comment thx!","listText":"Hi pls like and comment thx!","text":"Hi pls like and comment thx!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/180612601","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4745720,"gmtCreate":1623661313604,"gmtModify":1663228734945,"authorId":3569967413953406,"author":{"id":3569967413953406,"authorId":3569967413953406,"name":"desjen","avatar":"https://static.tigerbbs.com/4314e7f661d526ed72ecededb19043c2","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180612601,"type":1,"supId":4642219,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":4642280,"gmtCreate":1623201792658,"gmtModify":1663228247534,"authorId":3569967413953406,"author":{"id":3569967413953406,"authorId":3569967413953406,"name":"desjen","avatar":"https://static.tigerbbs.com/4314e7f661d526ed72ecededb19043c2","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180612601,"type":1,"supId":4642219,"prevId":0,"content":"Thanks and pls reply and like","text":"Thanks and pls reply and like","html":"Thanks and pls reply and like"},{"id":4642219,"gmtCreate":1623201621216,"gmtModify":1663228245460,"authorId":3573276404004652,"author":{"id":3573276404004652,"authorId":3573276404004652,"name":"Ak91","avatar":"https://static.tigerbbs.com/0578c6f4e6345562f2d636b87cc2b9fd","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180612601,"type":1,"supId":0,"prevId":0,"content":"Comment back pls","text":"Comment back pls","html":"Comment back pls"},{"id":4642254,"gmtCreate":1623201714756,"gmtModify":1635331411679,"authorId":3568071651427696,"author":{"id":3568071651427696,"authorId":3568071651427696,"name":"Pigmonkey","avatar":"https://static.tigerbbs.com/3402225c0172781df7553e20722ebad7","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180612601,"type":1,"supId":4642219,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":180639066,"gmtCreate":1623200960755,"gmtModify":1704198168895,"author":{"id":"3581913988119713","authorId":"3581913988119713","name":"Roticanai","avatar":"https://static.tigerbbs.com/4da10b7952b9a699e2c4703a67642740","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180639066","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180694602,"gmtCreate":1623200857406,"gmtModify":1704198165140,"author":{"id":"3574639507377836","authorId":"3574639507377836","name":"Kikiooi","avatar":"https://static.tigerbbs.com/81135f833a61d8d0899dff1c77b07e72","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Sometimes tihinong is the drug approval become too fast, lacking of longer analysis or long let term clinical data?&nbsp;","listText":"Sometimes tihinong is the drug approval become too fast, lacking of longer analysis or long let term clinical data?&nbsp;","text":"Sometimes tihinong is the drug approval become too fast, lacking of longer analysis or long let term clinical data?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180694602","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180607903,"gmtCreate":1623200574202,"gmtModify":1704198152531,"author":{"id":"3578540042073632","authorId":"3578540042073632","name":"Brandon2207","avatar":"https://static.tigerbbs.com/c0335fafe87a5d7a8728bb3763ba20dc","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/180607903","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4641864,"gmtCreate":1623200791444,"gmtModify":1663228243439,"authorId":3581853725647272,"author":{"id":3581853725647272,"authorId":3581853725647272,"name":"JerlinTan","avatar":"https://static.tigerbbs.com/06e97d9d1f6e585d5dc673ff8fcc8386","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.86%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180607903,"type":1,"supId":0,"prevId":0,"content":"done, pls response <u>back</u>","text":"done, pls response <u>back</u>","html":"done, pls response <u>back</u>"},{"id":4641986,"gmtCreate":1623201103250,"gmtModify":1663228240958,"authorId":3557433279201512,"author":{"id":3557433279201512,"authorId":3557433279201512,"name":"Couragesther","avatar":"https://static.tigerbbs.com/fb776fde22322bb11f3651d216a6b06e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180607903,"type":1,"supId":0,"prevId":0,"content":"Sure hElp comMent back","text":"Sure hElp comMent back","html":"Sure hElp comMent back"}],"langContent":"EN"},{"id":180606548,"gmtCreate":1623200464484,"gmtModify":1704198147937,"author":{"id":"3580565594783380","authorId":"3580565594783380","name":"A79","avatar":"https://static.tigerbbs.com/e27267c412cea01bdd4a47d746ba7606","vip":1,"crmLevel":9,"crmLevelSwitch":0},"htmlText":"Not sure abt thatBut like and comment here&nbsp;for good luck!","listText":"Not sure abt thatBut like and comment here&nbsp;for good luck!","text":"Not sure abt thatBut like and comment here for good luck!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/180606548","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4641772,"gmtCreate":1623200550290,"gmtModify":1663228245333,"authorId":3582022994702843,"author":{"id":3582022994702843,"authorId":3582022994702843,"name":"Shop","avatar":"https://static.tigerbbs.com/d361fd3c4c5677fff3957e6d430ecb52","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180606548,"type":1,"supId":4641747,"prevId":0,"content":"[Smile]","text":"[Smile]","html":"[Smile]"},{"id":4641747,"gmtCreate":1623200512569,"gmtModify":1663228243738,"authorId":3581888768537623,"author":{"id":3581888768537623,"authorId":3581888768537623,"name":"AhGong","avatar":"https://community-static.tradeup.com/news/9a621750f6ca11e5db28b9433a118ff1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180606548,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"},{"id":4641777,"gmtCreate":1623200567329,"gmtModify":1663228241334,"authorId":3578540042073632,"author":{"id":3578540042073632,"authorId":3578540042073632,"name":"Brandon2207","avatar":"https://static.tigerbbs.com/c0335fafe87a5d7a8728bb3763ba20dc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3582022994702843,"repliedAuthor":{"id":3582022994702843,"authorId":3582022994702843,"name":"Shop","avatar":"https://static.tigerbbs.com/d361fd3c4c5677fff3957e6d430ecb52","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":180606548,"type":1,"supId":4641747,"prevId":4641772,"content":"Please like back ","text":"Please like back ","html":"Please like back "}],"langContent":"EN"},{"id":180606239,"gmtCreate":1623200448521,"gmtModify":1704198147776,"author":{"id":"3571546243427161","authorId":"3571546243427161","name":"JaydenSee","avatar":"https://static.tigerbbs.com/f81b1d1b9ef76e9028b0f68e5a5d3553","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like and comments&nbsp;","listText":"Pls like and comments&nbsp;","text":"Pls like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/180606239","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4642047,"gmtCreate":1623201249032,"gmtModify":1663228247647,"authorId":3563150446821026,"author":{"id":3563150446821026,"authorId":3563150446821026,"name":"Acella","avatar":"https://static.tigerbbs.com/2712c4bb0bfbec4d2773e012189db3bc","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180606239,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"},{"id":4641866,"gmtCreate":1623200801864,"gmtModify":1663228244426,"authorId":3581853725647272,"author":{"id":3581853725647272,"authorId":3581853725647272,"name":"JerlinTan","avatar":"https://static.tigerbbs.com/06e97d9d1f6e585d5dc673ff8fcc8386","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.86%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180606239,"type":1,"supId":0,"prevId":0,"content":"done, pls response <u>back</u>","text":"done, pls response <u>back</u>","html":"done, pls response <u>back</u>"}],"langContent":"EN"},{"id":180606188,"gmtCreate":1623200432744,"gmtModify":1704198147285,"author":{"id":"3555914646523682","authorId":"3555914646523682","name":"nayoowin","avatar":"https://static.tigerbbs.com/15f0b006a5a32255f437afc5e32b6b80","vip":1,"crmLevel":9,"crmLevelSwitch":1},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180606188","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180601698,"gmtCreate":1623200382814,"gmtModify":1704198144835,"author":{"id":"3576284335652964","authorId":"3576284335652964","name":"Dickson8614","avatar":"https://static.tigerbbs.com/1c6a81e28879ea087b93c6234e7b7eb8","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":7,"crmLevelSwitch":1},"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/180601698","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4642050,"gmtCreate":1623201256504,"gmtModify":1663228245547,"authorId":3563150446821026,"author":{"id":3563150446821026,"authorId":3563150446821026,"name":"Acella","avatar":"https://static.tigerbbs.com/2712c4bb0bfbec4d2773e012189db3bc","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180601698,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"},{"id":4641733,"gmtCreate":1623200456321,"gmtModify":1663228245329,"authorId":3574384014717887,"author":{"id":3574384014717887,"authorId":3574384014717887,"name":"cutemiao","avatar":"https://static.tigerbbs.com/bb482433c2ea26132373994768ab7de2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180601698,"type":1,"supId":0,"prevId":0,"content":"Interesting.&nbsp; Like and comment back.&nbsp; <u>Thanks</u>","text":"Interesting.&nbsp; Like and comment back.&nbsp; <u>Thanks</u>","html":"Interesting.&nbsp; Like and comment back.&nbsp; <u>Thanks</u>"},{"id":4641724,"gmtCreate":1623200437896,"gmtModify":1663228245037,"authorId":3571546243427161,"author":{"id":3571546243427161,"authorId":3571546243427161,"name":"JaydenSee","avatar":"https://static.tigerbbs.com/f81b1d1b9ef76e9028b0f68e5a5d3553","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180601698,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":4641736,"gmtCreate":1623200461808,"gmtModify":1663228244550,"authorId":3555914646523682,"author":{"id":3555914646523682,"authorId":3555914646523682,"name":"nayoowin","avatar":"https://static.tigerbbs.com/15f0b006a5a32255f437afc5e32b6b80","vip":1,"currentWearingBadge":{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.10","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2006},"crmLevel":9,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180601698,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"},{"id":4641729,"gmtCreate":1623200445035,"gmtModify":1663228243947,"authorId":3566388443594959,"author":{"id":3566388443594959,"authorId":3566388443594959,"name":"YH999","avatar":"https://static.tigerbbs.com/bd93f967883fcc803fcb85d1b92ea97c","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180601698,"type":1,"supId":0,"prevId":0,"content":"reply <u>pls</u>","text":"reply <u>pls</u>","html":"reply <u>pls</u>"}],"langContent":"EN"},{"id":180601365,"gmtCreate":1623200377557,"gmtModify":1704198144183,"author":{"id":"3583324925442360","authorId":"3583324925442360","name":"EsmeT","avatar":"https://static.tigerbbs.com/2de5124e6af354a5501487b248f6a83b","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and comment too pls!&nbsp;","listText":"Like and comment too pls!&nbsp;","text":"Like and comment too pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/180601365","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4641702,"gmtCreate":1623200403197,"gmtModify":1663228244543,"authorId":3584083942205926,"author":{"id":3584083942205926,"authorId":3584083942205926,"name":"HappyTum","avatar":"https://static.tigerbbs.com/e17e8fe0f76bab142b7afa480ad9e85b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180601365,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":4641718,"gmtCreate":1623200433178,"gmtModify":1663228240957,"authorId":3583324925442360,"author":{"id":3583324925442360,"authorId":3583324925442360,"name":"EsmeT","avatar":"https://static.tigerbbs.com/2de5124e6af354a5501487b248f6a83b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180601365,"type":1,"supId":4641702,"prevId":0,"content":"Thanks!","text":"Thanks!","html":"Thanks!"}],"langContent":"EN"},{"id":180601972,"gmtCreate":1623200375996,"gmtModify":1704198144672,"author":{"id":"3583928404589069","authorId":"3583928404589069","name":"Jinroro","avatar":"https://static.tigerbbs.com/f7590444621e058dc68c183197065aa2","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180601972","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180603543,"gmtCreate":1623200364982,"gmtModify":1704198143858,"author":{"id":"3568089111846836","authorId":"3568089111846836","name":"Ladious","avatar":"https://static.tigerbbs.com/8c7a0777ad403c9882135b0067a24d7e","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Comment an like","listText":"Comment an like","text":"Comment an like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/180603543","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4641693,"gmtCreate":1623200386718,"gmtModify":1663228244940,"authorId":3583324925442360,"author":{"id":3583324925442360,"authorId":3583324925442360,"name":"EsmeT","avatar":"https://static.tigerbbs.com/2de5124e6af354a5501487b248f6a83b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180603543,"type":1,"supId":4641688,"prevId":0,"content":"??","text":"??","html":"??"},{"id":4641688,"gmtCreate":1623200375252,"gmtModify":1663228243935,"authorId":3568089111846836,"author":{"id":3568089111846836,"authorId":3568089111846836,"name":"Ladious","avatar":"https://static.tigerbbs.com/8c7a0777ad403c9882135b0067a24d7e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180603543,"type":1,"supId":0,"prevId":0,"content":"<u>help</u>","text":"<u>help</u>","html":"<u>help</u>"}],"langContent":"EN"},{"id":180609772,"gmtCreate":1623200321796,"gmtModify":1704198142390,"author":{"id":"3582022994702843","authorId":"3582022994702843","name":"Shop","avatar":"https://static.tigerbbs.com/d361fd3c4c5677fff3957e6d430ecb52","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"comment n like","listText":"comment n like","text":"comment n like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/180609772","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4641680,"gmtCreate":1623200354925,"gmtModify":1663228243633,"authorId":3566388443594959,"author":{"id":3566388443594959,"authorId":3566388443594959,"name":"YH999","avatar":"https://static.tigerbbs.com/bd93f967883fcc803fcb85d1b92ea97c","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180609772,"type":1,"supId":0,"prevId":0,"content":"reply <u>pls</u>","text":"reply <u>pls</u>","html":"reply <u>pls</u>"},{"id":4641684,"gmtCreate":1623200367005,"gmtModify":1635331470896,"authorId":3583324925442360,"author":{"id":3583324925442360,"authorId":3583324925442360,"name":"EsmeT","avatar":"https://static.tigerbbs.com/2de5124e6af354a5501487b248f6a83b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180609772,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":180609480,"gmtCreate":1623200321040,"gmtModify":1704198142554,"author":{"id":"3578570760040163","authorId":"3578570760040163","name":"hmmwvms","avatar":"https://static.tigerbbs.com/a906b2444a1aca7cd161a6e1ee03687e","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Headache","listText":"Headache","text":"Headache","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180609480","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":62,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}